Wednesday, May 8, 2013

Repligen HDAC inhibitors progress

›
5/7/13 - REPLIGEN CORP - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS . http://www.pharm...
Tuesday, May 7, 2013

Fatigue is frequent and multifactorial in Friedreich's ataxia

›
Fatigue is frequent and multifactorial in Friedreich's ataxia . Cynthia B. da Silva, Camila F. Chevis, Anelyssa D'Abreu, Iscia Lopes...

Non-Viral Gene Therapy Vectors Carrying Genomic Constructs

›
Non-Viral Gene Therapy Vectors Carrying Genomic Constructs George Kotzamanis, Hassan Abdulrazzak, Athanassios Kotsinas and Vassilis G. Gor...
Monday, May 6, 2013

Entrevista a Javier Díaz-Nido

›
Radio interview to Javier Diaz-Nido, Spanish Researcher on Friedreich's Ataxia (Spanish) Manuel Seara ha hablado sobre ataxia con Ja...
Sunday, May 5, 2013

Bioenergetics Reprogrammed in a Cellular Model of Friedreich's Ataxia: Frataxin Deficiency Affects Formation of Respiratory Supercomplexes and Down-regulates Both OXPHOS and Glycolysis.

›
Bioenergetics Reprogrammed in a Cellular Model of Friedreich's Ataxia: Frataxin Deficiency Affects Formation of Respiratory Supercomplex...
Thursday, May 2, 2013

Radial diffusivity in the cerebellar peduncles correlates with clinical severity in Friedreich ataxia

›
Radial diffusivity in the cerebellar peduncles correlates with clinical severity in Friedreich ataxia . Christian Clemm von Hohenberg, Mich...
Wednesday, May 1, 2013

Heme Levels Are Increased in Human Failing Hearts

›
Heme Levels Are Increased in Human Failing Hearts . Arineh Khechaduri, MS; Marina Bayeva, PhD; Hsiang-Chun Chang, BA; Hossein Ardehali, MD, ...
Saturday, April 27, 2013

Triple Therapy with Darbepoetin Alfa, Idebenone, and Riboflavin in Friedreich’s Ataxia: an Open-Label Trial

›
Triple Therapy with Darbepoetin Alfa, Idebenone, and Riboflavin in Friedreich’s Ataxia: an Open-Label Trial . Javier Arpa, Irene Sanz-Galle...

Progress in gene therapy for neurological disorders

›
Progress in gene therapy for neurological disorders . Michele Simonato, Jean Bennett, Nicholas M. Boulis, Maria G. Castro, David J. Fink, Wi...

Erythropoietin receptor (EpoR) agonism to treat a wide range of diseases.

›
Erythropoietin receptor (EpoR) agonism to treat a wide range of diseases. Sanchis-Gomar F, Perez-Quilis C, Lippi G.; Mol Med. 2013 Apr 11. ...